Mervenur Yavuz

Ms. Mervenur Yavuz


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Cureus
Verified
Journal Article
Open access
TDTuran Demircan
Turan Demircan
MYMervenur Yavuz
Mervenur Yavuz
EKEgemen Kaya
Egemen Kaya
SASıddıka Akgül
Sıddıka Akgül
EAEbru Altuntaş
Ebru Altuntaş
Glioblastoma multiform (GBM) is one of the most severe tumor types. It is highly invasive and characterized as a grade IV neoplastic cancer. Its resistance to chemotherapy-temozolomide (TMZ treatment)-in combination with tumor treating fields (TTFields), limits the cure of GBM. Therefore researchers are searching for new treatment options to increase the length of recurrence time and improve overall survival for GBM patients. Several cell lines have been established and are in use to understand the molecular basis of GBM and to test the developed drugs. On one hand, it is highly advantageous to utilize multiple cell lines with different genetic backgrounds to gain more insight into the characterization and treatment of the disease. However, on the other hand, characteristics of these cell lines such as proliferation rate, invasion, and colony formation capacity differ greatly among these cells. Hence, a detailed comparison concerning molecular and cellular features of commonly used cell lines is essential. In this study, cell proliferation and apoptosis rate, cell migration capacity, and gene expression profile of U87, Ln229, and SvGp12 cells have been investigated and compared.

Verified
Journal Article
Open access
PDF file
IKIlknur Keskin
Ilknur Keskin
BŞBegüm Şahin
Begüm Şahin
ABAziz Bülbül
Aziz Bülbül
MÇMustafa Çakır
Mustafa Çakır
MYMervenur Yavuz
Mervenur Yavuz
TDTuran Demircan
Turan Demircan
Colon cancer remains a leading cause of cancer-related deaths, and drug repurposing offers a promising strategy to identify new therapies. Hydroquinidine (HQ), a class I antiarrhythmic agent, has recently been suggested to possess anticancer properties; however, its preclinical safety and efficacy in colorectal cancer are not well defined. The safety of HQ was evaluated in Wistar rats following OECD guidelines. Rats received daily intraperitoneal doses (2.5–25 mg/kg) for 90 days, with hematological, biochemical, and histopathological assessments performed. HQ was well tolerated up to 12.5 mg/kg, whereas 25 mg/kg caused signs of hepatotoxicity without lethality. A 1,2-dimethylhydrazine-induced colorectal cancer model was then used to assess HQ at safe doses (6.25 and 12.5 mg/kg) compared with cisplatin. Tissue histopathology and selected molecular markers associated with inflammation, apoptosis, epithelial–mesenchymal transition, and PI3K/AKT/mTOR pathway activity were analyzed. In the DMH-induced colon cancer model, HQ improved colonic tissue architecture and was associated with lower histopathological scores compared with untreated tumor controls. HQ also modulated tumor-associated markers by reducing IL-6 immunoreactivity, increasing caspase-3 expression, enhancing E-cadherin immunoreactivity, and decreasing vimentin expression. Moreover, HQ was associated with reduced immunoreactivity of mTOR pathway-related markers, suggesting attenuation of pathway activation in this experimental context. Overall, HQ showed an acceptable safety profile at the selected doses and exerted favorable histopathological and molecular modulatory effects, supporting further investigation as a potential repurposing candidate.

22 August 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MYMervenur Yavuz
Mervenur Yavuz
FDFirli Rahmah Primula Dewi
Firli Rahmah Primula Dewi
IKIlknur Keskin
Ilknur Keskin
TDTuran Demircan
Turan Demircan
Background: Drug repurposing represents an accelerated and cost-effective approach to discovering novel oncologic therapeutics. Here, we investigated the anticancer potential and underlying mechanisms of marbofloxacin (MBF), a veterinary fluoroquinolone (FQ), against breast cancer (BC) cells. Methods: The cellular impacts of MBF on cell viability, anchorage-dependent growth, tumorigenicity, migration, apoptosis, proliferation, senescence, and mitochondrial function were thoroughly characterized. To further elucidate its mechanistic activity, real-time qRT-PCR, untargeted LC-MS/MS-based metabolomics, network pharmacology, and molecular docking analysis were integrated. Results: MBF suppressed BC cell growth by inhibiting cellular proliferation and migration, disrupting mitochondrial membrane potential, and inducing ROS-mediated apoptosis and irreversible cellular senescence. These phenotypic impacts were accompanied by upregulation of tumor suppressors such as CDKN1A and PUMA and downregulation of oncogenes including MKI67, BIRC5, and BCL-2. Metabolomic analysis revealed broad suppression of biosynthesis-related metabolic pathways, characterized by the depletion of critical polyamines and nucleotide pathways. Network pharmacology and molecular docking analyses identified EGFR and HSP90AA1 as putative hub proteins potentially associated with the observed anticancer phenotype. Conclusions: These results provide initial evidence that MBF induces metabolic and molecular rewiring in BC, highlighting its promise as a repositionable therapeutic candidate.

7 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
TDTuran Demircan
Turan Demircan
MYMervenur Yavuz
Mervenur Yavuz
SASıddıka Akgül
Sıddıka Akgül
Breast invasive cancer (BIC) is one of the most commonly observed and the deadliest cancer among women. Despite the progress that has been made in improving breast cancer outcomes by the development of advanced treatment options, due to the heterogeneity and complexity of the disease, more studies are required to explore underlying molecular mechanisms of breast cancer which may provide useful insights to overcome the constraints related to current therapeutic options. The goal of this study was to reveal the crucial roles of m6A regulatory proteins in BIC development using various publicly available datasets and databases. We first conducted a comprehensive analysis to depict the mutation frequency and types for m6A regulatory genes in sub-types of BIC for the evaluation of the genetic alterations landscape of breast cancer. Changes in expression levels of m6A regulatory factors were identified as the key genetic alteration in BIC. Implementation of Kaplan-Meier tool to assess the predictive value of m 6 A pathway components in BIC validated the use of VIRMA, METTL14, RBM15B, EIF3B, YTHDF1, and YTHDF3 as prognostic biomarkers of breast cancer. We then examined the enriched gene ontology (GO) terms and KEGG pathways for the tumor samples with genetic alterations in the m 6 A pathway. Dysregulation of m 6 A regulatory factors in BIC was associated with cell division and survival-related pathways such as ‘nuclear division’ and ‘chromosome segregation’ via the upregulation of the genes functioning in these biological processes and the gained overactivity of these pathways may account for poor prognosis of the disease. The performed analyses highlighted m 6 A pathway genes as potential regulators of BIC growth and as a valuable set to be utilized as clinical biomarkers in BIC disease.

26 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MYMervenur Yavuz
Mervenur Yavuz
TDTuran Demircan
Turan Demircan
Breast cancer is a molecularly heterogeneous disease in which therapeutic resistance and metastatic relapse continue to limit the benefits of endocrine, (human epidermal growth factor receptor 2) HER2-targeted, immune, and cytotoxic therapies. Accumulating evidence indicates that breast cancer cells co-opt voltage-gated sodium and calcium channels, diverse potassium channel subfamilies, hyperpolarization-activated cyclic nucleotide-gated channels (HCN), transient receptor potential (TRP) channels, chloride channels, purinergic receptors, and mechanosensitive channels to regulate membrane potential, proliferation, invasion, metastatic competence, immune suppression, and treatment resistance. Although these proteins originate from distinct gene families, their oncogenic outputs converge on a restricted set of signaling nodes, including epithelial-to-mesenchymal transition programs, pH-dependent matrix remodeling, PI3K/AKT/mTOR signaling, Ca2+-ROS homeostasis, autophagy, and regulated cell death pathways. This convergence creates opportunities to repurpose clinically used cardiovascular, neurological, anesthetic, and anti-infective drugs. The strongest current candidates include ranolazine and phenytoin for Nav1.5, ivabradine for HCN2/3, perioperative lidocaine, and the historically investigated chemosensitizer verapamil. However, target engagement, clinically achievable exposure, molecular subtype dependence, and on-target cardiac or neurological toxicity remain significant constraints. This review integrates channel biology with drug repurposing evidence, distinguishes approved drugs from experimental pharmacological probes, introduces a tiered framework based on mechanistic validation and translational readiness, and identifies subtype-stratified organoid and patient-derived xenograft testing as key steps toward precision oncology.